Amicus Therapeutics and the Treatment of Rare Diseases

Amicus Therapeutics is a biotechnology company that focuses on researching treatment for rare and orphan diseases. Although the company is based in Cranbury, New Jersey, they operate a second research site in San Diego, California. Amicus was founded in 2002 but didn’t go public until 2007. The company is fairly small, with around five hundred employees. Amicus is primarily research based and has to have other companies take care of manufacturing. Although the company offers no products as of 2017, a few potential products are in the final stages of being approved for commercial use.

https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo

Fabry Disease is one illness that Amicus Therapeutics is currently researching. The company has developed two potential products to help treat it: Galafold/Migalastat Monotherapy and novel ERTs (Enzyme Replacement Therapy). Galafold is an orally administered monotherapy that has full approval in Europe and is ready to be released to the public. Migalastat Monotherapy and Galafold are one in the same, with Galafold being the brand name. While the product is ready for use in Europe, it is still in the approval stages in the Americas and the rest of the world. Amicus’ ERTs for Fabry Disease are in preclinical stages of research.
In addition to Fabry Disease, Amicus Therapeutics studies two other illnesses specifically, Pompe Disease and Epidermolysis Bullosa. Their product for Pompe Disease, a novel ERT named ATB200 and AT2221 are in the middle of the final phase of testing. This treatment will require a chaperone as well. Amicus’ medication for Epidermolysis Bullosa is named SD-101. It is a topical medication. Currently, SD-101 is in the third and final phase of testing.
While Amicus Therapeutics focuses on a few diseases specifically, they also conduct research on other rare diseases and plan treatments for patients with these illnesses. Most of their medications for these various diseases are novel ERTs and most of them are in the primary research phase of development.
Dedicated to research and creating treatments for those with rare illnesses, Amicus Therapeutics is a company to keep an eye on. Several products are nearing their final stages and are one step closer to helping others survive.
More here: Crunchbase

Sheldon Lavin: The Brilliant CEO Of OSI Group

Sheldon Lavin is one of the most crucial people in OSI Group and has played a major part in the company’s success in recent times. Sheldon Lavin leads the company from his position of CEO and has proven to be a perfect fit for the company. Sheldon Lavin, however, did not start out in the field of meat production, but rather in the field of finance.

Infact, before Sheldon Lavin worked at OSI Group, the company was one of his clients. In the 1970s, when the company was undergoing a significant change with their production, Sheldon Lavin was responsible for making sure that the company’s finances were in order and that everything was fine with the deals that they had with some large clients. He worked extremely closely with the leadership of OSI at the time and then decided to switch over to the company and work full time.

Sheldon Lavin has been extremely beneficial to OSI group and has set in motion numerous changes which have improved the working of the company. He was responsible for the company’s recent upgrade in technology which they use for their processing units. One of the reasons why OSI group has managed to stay atop the competition is because they have constantly adapted to everything that is new in the meat processing industry – right from the machines they use, to their packaging.

As CEO, Sheldon Lavin is one of the most vital parts of the company and works alongside the leaders to ensure that the company gives their clients the best product possible. He was also instrumental in taking OSI Group to international waters. Currently, OSI Group has its production units in countries like China. McDonald’s’ there as well are being supplied with meat by OSI Group, making them a truly globalized company.

What makes Sheldon Lavin such a Great CEO is the fact that he is dedicated to the success of OSI Group. A food lover himself, he tries his best to ensure that OSI Group is always putting out only the highest grade of products for their clients and their consumers.

Learn more about Sheldon Lavin on http://www.bizjournals.com/chicago/potmsearch/detail/submission/6423650/Sheldon_Lavin